Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Amylyx Pharmaceuticals Inc’s stock clocked out at $13.25, up 3.76% from its previous closing price of $12.77. In other words, the price has increased by $3.76 from its previous closing price. On the day, 1.67 million shares were traded. AMLX stock price reached its highest trading level at $13.32 during the session, while it also had its lowest trading level at $12.62.
Ratios:
To gain a deeper understanding of AMLX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.72 and its Current Ratio is at 8.72. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On June 24, 2025, Guggenheim started tracking. The Stock assigning a Buy rating and target price of $17. On June 17, 2025, Citigroup started tracking. The Stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when Mazzariello Gina sold 15,000 shares for $8.34 per share. The transaction valued at 125,046 led to the insider holds 156,969 shares of the business.
Mazzariello Gina sold 15,000 shares of AMLX for $121,102 on Aug 12 ’25. The Chief Legal Officer now owns 171,969 shares after completing the transaction at $8.07 per share. On Aug 12 ’25, another insider, GINA MAZZARIELLO, who serves as the Officer of the company, bought 30,000 shares for $7.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1413343488 and an Enterprise Value of 1006604480. Its current Enterprise Value per Revenue stands at -4042.588 whereas that against EBITDA is -5.128.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.40, which has changed by 3.2741938 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $13.10, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of. The Stock is 46.79%, while the 200-Day Moving Average is calculated to be 139.86%.
Shares Statistics:
It appears that AMLX traded 1.76M shares on average per day over the past three months and 2309520 shares per day over the past ten days. A total of 89.16M shares are outstanding, with a floating share count of 79.58M. Insiders hold about 25.39% of the company’s shares, while institutions hold 70.84% stake in the company. Shares short for AMLX as of 1756425600 were 8410918 with a Short Ratio of 4.78, compared to 1753920000 on 7192631. Therefore, it implies a Short% of Shares Outstanding of 8410918 and a Short% of Float of 10.3999995.
Earnings Estimates
The current rating of Amylyx Pharmaceuticals Inc (AMLX) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.32 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.45 and -$2.02 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.49, with 7.0 analysts recommending between -$0.81 and -$1.97.
